Table 1.
Demographics and scanning parameters of study cohorts.
| Malignant | Benign | P‐value | |
|---|---|---|---|
| Development | |||
| Subjects | 74 | 289 | – |
| Study (COPDGene:NLST:LungX) | 30:6:38 | 239:8:42 | <0.001c |
| Age, yrs (mean ± SD) | 65.5 ± 11.3 | 53.2 ± 13. | <0.001 |
| Sex (Female: Male) | 34:40 | 179:110 | <0.001c |
| Pack‐yearsa, yrs (mean ± SD) | 37.7 ± 30.4 | 10.7 ± 15.7 | <0.001 |
| Nodule size, mm Range (mean ± SD) | 5–30 (13.6 ± 6.2) | 4–30 (7.79 ± 13.3) | <0.001 |
| Nodule size ≤ 15mm | 50 | 240 | 0.005c |
| LDCT screening eligiblea (Yes: No) | 33:3 | 69:178 | <0.001c |
| Kilovoltage, kVp (range, mean) | 120–120, 120 | 120–120, 120 | 1.00 |
| Tube current, mA (range, mean) | 60–440,b 339 | 40–500,b 330 | 0.89 |
| Slice thickness, mm (range, mean) | 0.6–1.3, 0.8 | 0.6–1.3, 0.7 | 0.97 |
| CT manufacturer (GE:Philips:Siemens) | 19:35:20 | 86:97:106 | <0.001c |
| Validation | |||
| Subjects | 50 | 50 | – |
| Age (mean ± SD) | 64.0 ± 10.7 | 62.5 ± 10.9 | 0.456 |
| Sex (Female: Male) | 35:15 | 31:19 | 0.339c |
| Pack‐yearsa, yrs (mean ± SD) | 33.5 ± 30.1 | 30.1 ± 23.6 | 0.505 |
| Nodule size, mm Range (mean ± SD) | 5–30 (19.9 ± 7.4) | 9–30 (13.66 ± 4.8) | <0.001 |
| Nodule size ≤ 15mm | 17 | 35 | <0.001c |
| LDCT screening eligible (Yes: No) | 18:32 | 16:34 | 0.674c |
| Kilovoltage, kVp (range, mean) | 120–120 , 120 | 120–120 , 120 | 1.00 |
| Tube Current, mA (range, mean) | 160–351, 237 | 160–386, 265 | 0.62 |
| Slice thickness, mm (range, mean) | 0.6–0.8, 0.7 | 0.6–0.8, 0.7 | 0.98 |
| CT Manufacturer (GE:Philips:Siemens) | 17:19:14 | 16:22:12 | 0.817c |
COPD, chronic obstructive pulmonary disease; NLST, National Lung Screening Trial; SD, standard deviation; LDCT, low‐dose computed tomography; GE, General Electric.
a
smoking pack‐year data were not available for the LungX Challenge.
b
low‐dose NLST scans included were reconstructed to higher resolution at time of acquisition.
c
discrete (categorical) data significance performed with chi‐square test.